LOTUS Edge™ TAVR technology will improve outcomes for those with severe aortic stenosis. Commentary by Dr. Ian Meredith, global chief medical officer.

In STAT News, Dr. Ian Meredith, global chief medical officer at Boston Scientific, discusses the evolution of minimally invasive transcatheter aortic valve replacement (TAVR) technology and the clinical benefits of the newly FDA-approved LOTUS Edge Aortic Valve System for the treatment of high-risk patients with severe aortic stenosis.

Characterized by narrowing of the aortic valve of the heart, aortic stenosis is the most common valvular heart disease in the world, affecting approximately 7 percent of the population over age 65.1 From the onset of symptoms, the average survival rate is 50 percent at two years and 20 percent at five years without aortic valve replacement.2,3

The LOTUS Edge valve provides patients who aren't good candidates for traditional open-heart surgery a safe and effective treatment alternative to restore proper function to their severely narrowed aortic valve, with several clinical features that set it apart from other valves on the market.

Read Dr. Meredith’s full piece here.